VTI1B抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-7: Human kidney tissue, RAW264.7 cell, Mouse kidney tissue, Human lung tissue, Human fetal liver tissue, Hela and 231 cell lysates , Primary antibody: P02323(VTI1B Antibody) at dilution 1/300, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 5 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P02323(VTI1B Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P02323(VTI1B Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The VTI1B antibody is designed to target the vesicle transport through interaction with t-SNAREs 1B (VTI1B) protein, a key component of the SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) family involved in intracellular membrane trafficking. VTI1B facilitates vesicle docking and fusion by mediating the formation of SNARE complexes, particularly in endosomal and Golgi-related transport pathways. It plays a critical role in maintaining cellular homeostasis, neurotransmitter release, and protein sorting.

Antibodies against VTI1B are widely used to study its expression, localization, and interaction partners in various biological contexts. Research has linked VTI1B dysfunction to neurological disorders, such as Alzheimer’s disease, and cancer, where altered membrane trafficking contributes to tumor progression. These antibodies are typically validated in applications like Western blotting, immunofluorescence, and immunoprecipitation, often utilizing models ranging from cultured cells to animal tissues.

Commercial VTI1B antibodies are commonly produced in rabbits or mice, with epitopes targeting specific conserved regions of the protein. Recent studies also employ CRISPR/Cas9-based knockout controls to confirm antibody specificity. As interest in membrane trafficking mechanisms grows, VTI1B antibodies remain essential tools for elucidating its physiological and pathological roles, offering insights into therapeutic strategies for trafficking-related diseases.